Lakefront Biotherapeutics (LKFT) Gross Margin (2021 - 2026)
Lakefront Biotherapeutics (LKFT) posted quarterly Gross Margin of 25.95% for Q1 2026, down 5574.0% year-over-year from 0.47% in Q1 2025, and down 74.03% quarter-over-quarter from 99.95% in Q4 2025.
Powered by 
Analysis
Lakefront Biotherapeutics (LKFT) Gross Margin (2021 - 2026) Analysis & Trends
Lakefront Biotherapeutics (LKFT) has reported Gross Margin for 6 consecutive years, with 25.95% the latest figure, recorded in Q1 2026.
- In Q1 2026, Gross Margin fell 5574.0% year-over-year to 25.95%; the TTM figure through Mar 2026 stood at 98.01% (up 1217.0% YoY), while the FY2025 annual figure was 97.33%, up 997.0% from the prior year.
- Gross Margin slipped to 25.95% in Q1 2026 per LKFT's latest filing, from 99.95% in the prior quarter.
- Across five years, Gross Margin topped out at 99.95% in Q4 2025 and bottomed at 25.95% in Q1 2026.
- Historically, Gross Margin has averaged 86.65% across 5 years, with a median of 90.62% in 2023.
- Annual changes were most pronounced in 2025 — Gross Margin soared 1473 bps — and 2026, when it slumped 5574 bps.
- Lakefront Biotherapeutics' Gross Margin stood at 97.71% in 2022, then fell by 14 bps to 83.97% in 2023, then rose by 1 bps to 85.22% in 2024, then rose by 17 bps to 99.95% in 2025, then plunged by 74 bps to 25.95% in 2026.
- Business Quant data shows LKFT's Gross Margin at 25.95% in Q1 2026, 99.95% in Q4 2025, and 84.7% in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 35.86% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 89.76% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 76.90% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 84.20% |
| 10 | Lakefront Biotherapeutics | 1.88 Bn | 1.88 Bn | 3.51 Mn | 24.90% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 24.90% |
| Mar 31, 2026 | 25.95% |
| Dec 31, 2025 | -3,197.73% |
| Sep 30, 2025 | 84.70% |
| Jun 30, 2025 | 92.85% |
| Mar 31, 2025 | 81.69% |
| Dec 31, 2024 | 95.47% |
| Sep 30, 2024 | 89.49% |
| Jun 30, 2024 | 97.87% |
| Mar 31, 2024 | 95.92% |
| Dec 31, 2023 | 96.69% |
| Sep 30, 2023 | 90.62% |
| Jun 30, 2023 | 92.96% |
| Mar 31, 2023 | 93.90% |
| Dec 31, 2022 | 102.45% |
| Sep 30, 2022 | 98.21% |
| Jun 30, 2022 | 98.12% |
| Mar 31, 2022 | 97.86% |
| Dec 31, 2021 | 101.11% |
| Sep 30, 2021 | 99.78% |